WEST LAFAYETTE, IN, Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round.
Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
